Rafarma Pharmaceuticals, Inc. (RAFA) announces plans for PCAOB-Registrant Audit and Streamlining of Corporate Structure to Upgrade Market Listing.
MOSCOW, Sept. 19, 2013 /PRNewswire/ — Rafarma Pharmaceuticals (OTC:RAFA), in an effort to upgrade its market listing has announced plans for a full audit and a streamlining of its corporate structure.
With recent advancements in production contract business development, as well as interest from several strategic partners, Rafarma will engage the services of a PCAOB registered audit firm. The Company also plans to streamline its corporate structure which will greatly lower administrative costs.
“This is the next step in Rafarma’s maturity in the public markets,” stated CEO Dave Anderson. “We’re excited at the opportunity to upgrade our listing in the U.S and abroad.”
About Rafarma Pharmaceuticals, Inc.
Operating from a new 270,000 square-foot state-of-the-art manufacturing and distribution facility in Russia, Rafarma Pharmaceuticals produces generic antibiotics and specialty pharmaceuticals in addition to its own line of proprietary products that are approved by the Ministry of Health of Russian Federation. For the last three years, the Russian Government has been highly focused on bolstering the development of the nation’s domestic pharmaceutical industry. Rafarma Pharmaceuticals’ mission is to work with the auspices of aggressive federal initiatives to fast-track the modernization of Russia’s pharmaceutical industry.
For more information on Rafarma Pharmaceuticals, visit: http://rafarma.com
Safe Harbor Statement
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words “anticipate,” “believe,” “estimate,” “may,” “intend,” “expect” and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance.
SOURCE Rafarma Pharmaceuticals, Inc. (RAFA)